Exploratory study of brentuximab vedotin (SGN-35), a novel monoclonal antibody-drug-conjugate against CD30, in mycosis fungoides (MF) and Sézary syndrome (SS) demonstrates clinical responses regardless of CD30 expression levels Meeting Abstract

  

Authors:	Bashey, S.; Krathen, M.; Sutherland, K.; Sundram, U.; Lingala, B.; Horwitz, S.; Hoppe, R.; Pulitzer, M.; Advani, R.; Kim, Y.
Abstract Title:	Exploratory study of brentuximab vedotin (SGN-35), a novel monoclonal antibody-drug-conjugate against CD30, in mycosis fungoides (MF) and Sézary syndrome (SS) demonstrates clinical responses regardless of CD30 expression levels
Meeting Title:	75th Anniversary Celebration of the Society for Investigative Dermatology (2012 SID Annual Meeting)
Journal Title:	Journal of Investigative Dermatology
Volume:	132
Issue:	Suppl. 1
Meeting Dates:	2012 May 9-12
Meeting Location:	Raleigh, NC
ISSN:	0022-202X
Publisher:	Elsevier Science, Inc.
Date Published:	2012-05-01
Start Page:	S95
Language:	English
ACCESSION:	WOS:000302866900562
PROVIDER:	wos
PUBMED:	22532972
DOI:	10.1038/jid.2012.86
Notes:	Meeting Abstract: 560 -- "Source: Wos"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/26416